Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Business Wire•17/11/2026•09:04 ET
1
Key Highlights
- ➤60 mg remlifanserin narrowly missed primary endpoint, improving SAPS-H+D by 2.2 points versus placebo
- ➤60 mg remlifanserin achieved nominal significance on CGI-S-ADP, with p=0.0077
- ➤Week 6 CGI-I-ADP improvement reached 44.0% with 60 mg versus 31.8% placebo
- ➤Week 6 NPI/NPI-NH psychosis change was −7.3 versus −5.9 for placebo
- ➤Acadia continues Phase 3 RADIANT development for Alzheimer’s disease psychosis
Expert Statements
Sanjeev Pathak, M.D., Senior Vice President, Head of Clinical Development at Acadia Pharmaceuticals
“These new analyses strengthen the evidence of a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis and timepoints. The observed dose-response pattern, together with new insights into the relationship between baseline psychosis severity and estimated treatment effect, further reinforces our confidence in the activity of remlifanserin as we continue Phase 3 development.”
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
− New analyses show a consistent efficacy signal with once-daily 60 mg remlifanserin across multiple measures of psychosis, with larger estimated treatment effects with increasing baseline psychosis severity
Get started
Create a free account to read the full story.
